Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

Mattia Mori; Francesca Moraca; Davide Deodato; Davide M. Ferraris; Petra Selchow; Peter Sander; Menico Rizzi; Maurizio Botta

doi:10.1016/j.bmcl.2014.04.004

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

Mattia Mori
, Francesca Moraca
, Davide Deodato
, Davide M. Ferraris
, Petra Selchow
, Peter Sander
, Menico Rizzi
, Maurizio Botta

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a K_i of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.

Original language	English
Pages (from-to)	2508-2511
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	24
Issue number	11
DOIs	https://doi.org/10.1016/j.bmcl.2014.04.004
Publication status	Published - 1 Jun 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Enzyme inhibitors
Metalloproteases
Tuberculosis
Virtual screening
Zmp1

Access to Document

10.1016/j.bmcl.2014.04.004

Cite this

@article{ac34b0f5f7e740109250a96f83cde110,

title = "Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor",

abstract = "The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a Ki of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.",

keywords = "Enzyme inhibitors, Metalloproteases, Tuberculosis, Virtual screening, Zmp1",

author = "Mattia Mori and Francesca Moraca and Davide Deodato and Ferraris, \{Davide M.\} and Petra Selchow and Peter Sander and Menico Rizzi and Maurizio Botta",

note = "Funding Information: This work was partially supported by the European Union FP7 program (Project SysteMTb HEALTH-F4-2010-241587). Research in the laboratory of P.S. is supported by Swiss National Science Foundation , EU NewTBVac (No. 241 745 ) and Tuberculosis Vaccine Initiative (TBVI). ",

year = "2014",

month = jun,

day = "1",

doi = "10.1016/j.bmcl.2014.04.004",

language = "English",

volume = "24",

pages = "2508--2511",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

AU - Mori, Mattia

AU - Moraca, Francesca

AU - Deodato, Davide

AU - Ferraris, Davide M.

AU - Selchow, Petra

AU - Sander, Peter

AU - Rizzi, Menico

AU - Botta, Maurizio

N1 - Funding Information: This work was partially supported by the European Union FP7 program (Project SysteMTb HEALTH-F4-2010-241587). Research in the laboratory of P.S. is supported by Swiss National Science Foundation , EU NewTBVac (No. 241 745 ) and Tuberculosis Vaccine Initiative (TBVI).

PY - 2014/6/1

Y1 - 2014/6/1

N2 - The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a Ki of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.

AB - The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a Ki of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.

KW - Enzyme inhibitors

KW - Metalloproteases

KW - Tuberculosis

KW - Virtual screening

KW - Zmp1

UR - https://www.scopus.com/pages/publications/84899968464

U2 - 10.1016/j.bmcl.2014.04.004

DO - 10.1016/j.bmcl.2014.04.004

M3 - Article

SN - 0960-894X

VL - 24

SP - 2508

EP - 2511

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 11

ER -

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this